Uniqure NV (QURE) reported disappointing financial results for the third quarter of fiscal 2025, with earnings per share (EPS) of $-1.38, falling short of Wall Street's consensus estimate of $-0.92 by $0.46. Revenue remained at $0.0B, matching expectations but indicating challenges in generating sales.
The company, which specializes in the discovery, development, and commercialization of innovative gene therapies, is headquartered in Amsterdam and employs 209 full-time staff. Its lead product candidate, AMT-061, is currently in a pivotal dosing phase for hemophilia B, while AMT-130 is undergoing a Phase I/II clinical study for Huntington’s disease.
Uniqure NV will host an earnings conference call at 8:00 AM EST to discuss these results and provide further insights into its operational performance and financial health. Missing analyst expectations could reflect ongoing challenges within the business or broader market conditions.
Investors are encouraged to review the full earnings release and listen to management’s commentary for a comprehensive understanding of the quarter's performance and future outlook. The company is set to report its next earnings on February 24, 2026, with EPS estimated at $-0.94 and revenue projected at $6.1M.